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Background: The optimal revascularization strategy for patients with impaired glomerular filtration rate (IGFR) has
not been established in acute coronary syndrome (ACS). We investigated the prognosis and impact of IGFR and
invasive strategy on the cardiovascular outcomes in the ACS population.
Methods: In a Taiwan national-wide registry, 3093 ACS patients were enrolled. The invasive strategy was defined as
patients with ST-elevation ACS (STE-ACS) undergoing primary angioplasty or fibrinolysis or coronary angiography
with intent to revascularization performed within 72 hours of symptom onset in non-ST-elevation ACS (NSTE-ACS).
IGFR was defined as an estimated GFR of less than 60 ml/min per 1.73 m2. Primary endpoint was a composite of
death, non-fatal myocardial infarction or stroke at one year.
Results: Patients with IGFR (n = 1226) had more comorbidities but received less evidence-based medications during
admission than those without IGFR (n = 1867). The primary endpoint-free survival rate is lower in the IGFR patients,
in the whole, STE-ACS and NSTE-ACS population (all log-rank tests p < 0.01). Cox regression analysis revealed IGFR
subjects had higher primary endpoint after adjusting by age, sex, medication at discharge and traditional risk factors
(all p < 0.01). Kaplan–Meier curves showed IGFR patients without invasive strategy had the worst outcome in the
STE-ACS and NSTE-ACS population (both p < 0.01). The invasive strategies, either with early angiography only or
angioplasty, were associated with reduced primary endpoints among IGFR patients in the NSTE-ACS population
(both p ≦ 0.024).
Conclusions: IGFR patients suffering from ACS had poor prognosis and an invasive strategy could improve
cardiovascular outcome in the NSTE-ACS population.
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Chronic kidney disease (CKD) is a global problem [1].
Patients with CKD have higher risk of progression to
end-stage renal disease (ESRD) and poor cardiovascular
prognosis [2]. Taiwan has been recognized as an epidemic
area of kidney disease with the highest incidence and
prevalence rates of ESRD in the world [3]. Although the
nationwide CKD Preventive Project with multidisciplinary
care program has proved its effectiveness in decreasing
dialysis incidence, mortality and medical costs, the number
of patients with CKD is still growing due to the increas-
ing prevalence of comorbidities, such as hypertension
and diabetes, in Taiwan as well as in the worldwide
[4]. Therefore, the development of effective treatment
strategies is mandatory for such a high cardiovascular
risk population.
The presence of endothelial dysfunction, inflammation,
dyslipidemia and activation of the renin-angiotensin sys-
tem are the main mechanisms by which CKD can induce
or complicate cardiovascular disease [5]. Therefore, CKD
is not only a coronary risk equivalent for ascertainment of
coronary risk but also a risk factor for the development
and progression of cardiovascular disease (CVD) [6].
Furthermore cardiovascular death is the leading cause
of mortality in the CKD population. Among the patients
admitted due to acute coronary syndrome (ACS), those
with CKD consistently have a poorer prognosis [7,8]. Al-
though recent major clinical trials have shown aggressive
medication treatment can improve cardiovascular outcome
in patients suffering from ACS, only few patients with
impaired glomerular filtration rate (IGFR) were enrolled.
In addition to the medical treatment, coronary revas-
cularization such as percutaneous coronary intervention
(PCI) is also proven to reduce cardiovascular morbidity
and mortality in the ACS patients. However, limited studies
investigated the impact of an invasive strategy on clinical
endpoints in patients with ACS and IGFR, as many trials of
revascularization excluded patients with IGFR [9]. Further-
more, with some evidence support, many physicians hesi-
tate to perform coronary angiography and revascularization
in IGFR patients because of the possibility of contrast-
induced nephropathy.
The current analysis from Taiwan ACS Full Spectrum
Registry therefore focuses on the prognosis and cardiovas-
cular outcomes of invasive strategy in ACS patients with
IGFR, including primary angioplasty or fibrinolysis for
ST-elevation (STE-ACS) and early invasive strategy (EIS)
for non-ST-elevation patients (NSTE-ACS) [10].
Methods
Study design
The study was a prospective, national, multicenter,
non-interventional, observational design. Patients recruit-
ment, definition of ACS, inclusion and exclusion had beenpreviously described in detail [11]. Patient data, such as
baseline characteristics, risk factors, clinical presenta-
tion, clinical diagnosis, in-hospital interventions as well
as medications prescribed, were collected from admis-
sion to discharge. Patients were followed up at months
3, 6, 9 and 12 post-discharge and data was collected on
medication usage, revascularization strategy as well as
clinical events, like death, myocardial infarction, stroke,
revascularization and hospitalization. Monitoring for
source documentation and accuracy was performed in
5% of all case report forms at each recruiting site. This
study was carried out in accordance with the local
regulatory guidelines and international guidelines for
Good Epidemiological Practice [12]. Ethics committee
approval was obtained at all trial sites including China
University Medical Hospital, Taoyuan General Hospital,
Wan-Fang Hospital, Show Chwan Memorial Hospital, Chia-
Yi Christian Hospital, Kuang Tien General Hospital,
National Taiwan University Hospital, Cheng Ching
Hospital, Sin Lau Hospital The Presbyterian Church of
Taiwan, Tainan Municipal Hospital, Mackay Memorial
Hospital, E-Da Hospital, Chi-Mei Hospital, Taichung
Armed Forces General Hospital, Taipei Tzu Chi General
Hospital, Kaohsiung Medical University Chung-Ho
Memorial Hospital, Taichung Veterans General Hospital,
Pingtung Christian Hospital, Lo-Tung Po-Ai Hospital,
Far Eastern Memorial Hospital, National Cheng Kung
University Hospital, National Taiwan University Hospital,
Yun-lin Branch, Dalin Tzuchi General Hospital, Kee-lung
Hospital, Taipei Veterans General Hospital, Cathay General
Hospital, Kaohsiung Veterans General Hospital, Taipei
Medical University Hospital, Shin Kong Wu Ho-Su
Memorial Hospital, Changhua Christian Hospital, National
Taiwan University Hospital, Chung Shan Medical University
Hospita, Hualien Tzu Chi General Hospital, Mackay
Memorial Hospital, Taitung Branch, Linkou Chang Gung
Memorial Hospital, Hsin Chu General Hospital, Kaohsiung
Chang Gung Memorial Hospital, Tri-Service General
Hospital and Cheng-Hsin Hospital. Written informed
consent was obtained from each patient.
Invasive strategy was defined as reperfusion done either
by primary angioplasty or thrombolysis in STE-ACS or
diagnostic coronary angiography (DCA) with intent to re-
vascularization performed within 72 hours of symptom
onset as early invasive strategy in NSTE-ACS.
Calculation of kidney function and definition of IGFR
Creatinine was analyzed by the Jaffe-kinetic method in
the central laboratory of each hospital. Baseline creatinine
was defined as creatinine measurement at time of presenta-
tion. The estimated glomerular filtration rate (eGFR) was
calculated using the Chronic Kidney Disease Epidemiology
Collaboration equation [13]. IGFR was defined as a eGFR
less than 60 ml/min per 1.73 m2. This range corresponds to
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classification scheme and helps identify individuals with
clinically significant CKD [14].
Statistical analyses
All data were expressed as mean ± standard deviation
(SD). For comparability between groups, a chi-square
test was used for categorical variables and analysis of
variance (ANOVA) was adopted for continuous vari-
ables. One-year survival analysis was performed and
the time to event was estimated according to the
Kaplan-Meier method and compared using the log-
rank test. Cox regression analysis was conducted to
calculate hazard ratio for CVD after adjusting co-variables
including age, sex and evidence-based medicines at
discharge (aspirin, clopidogrel, ACE inhibitor, angio-
tensin II receptor blocker, oral b-blocker and statin),
dyslipidemia, hypertension, diabetes, smoking and family
history. Analyses were conducted as time to first event
without double counting of events within analyses in-
volving composite endpoints.
The primary outcome was the composite of death,
non-fatal myocardial infarction and non-fatal stroke at
one year. The secondary outcome was the composite of
death, non-fatal myocardial infarction, non-fatal stroke,
re-hospitalization and revascularization at one year. We
analyzed the whole, STE-ACS and NSTE-ACS populations
separately. Statistical analysis was performed using SAS
software version 9.2 (SAS Institute Inc., Cary, NC, USA).
All statistical analyses were performed using a level




A total of 3183 eligible patients were enrolled between
October 2008 and January 2010 at 39 medical centers
and regional hospitals in Taiwan [9]. Among them, 3093
(97.1%) subjects with renal parameters and 12 months
outcome data were analyzed in this study and 1631
(52.7%) patients were STE-ACS. The mean age of the
3093 patients was 63.11 ± 13.50 years old and 78.2% of
the patients were males.
Baseline creatinines were 2.74 ± 2.59 and 0.94 ± 0.18 mg/dl
in the IGFR (n = 1226) and non-IGFR (n = 1867) groups,
respectively. Compared with the non-IGFR patients,
those with IGFR were older, thinner, lower diastolic
blood pressure and faster heart rate and had lower per-
centage of male patients at presentation. Comorbidities,
including hypertension, diabetes, previous coronary artery
disease (CAD), previous cerebrovascular accident (CVA)
and previous heart failure, were more common in IGFR
group but percentage of smoking and family history of
CAD were lower (Table 1).Pharmacological management during admission and
at discharge
Medications prescribed during the first 24 hours and
at discharge are shown in Figure 1. Class I guideline-
recommended agents including aspirin, clopidogrel,
β-blocker, angiotensin converting enzyme inhibitor and
statins were significantly less prescribed during admis-
sion and at discharge in patients with IGFR than those
without IGFR, with the exception of angiotensin recep-
tor antagonist.
Cardiovascular outcome and IGFR
During admission, the mortality in IGFR patients was
significantly higher (3.18% vs 0.59%, p < 0.01) but risks
of in-hospital infarction and stroke were similar com-
pared with non-IGFR subjects. In-hospital acute renal
failure happened more frequently in the IGFR than non-
IGFR patients (4.40% vs. 0.32%, p < 0.01).
Kaplan-Meier survival analysis showed that IGFR was
associated with higher primary and secondary outcome
for the whole, STE-ACS and NSTE-ACS populations at
one year (all p < 0.01) (Figure 2). Cox regression analysis
found the adjusted hazard ratio (HR) of presence of IGFR in
the whole, STE-ACS and NSTE-ACS populations were 1.98
(95% confidence interval (CI): 1.44-2.73), 1.78 (CI: 1.17-2.72)
and 2.27 (CI: 1.38-3.74) for the primary endpoint, respect-
ively (all p < 0.01). For the secondary endpoint, the HR of
presence of IGFR in the whole, STE-ACS and NSTE-ACS
populations were 1.25 (CI: 1.07-1.45), 1.17 (CI: 0.96-1.44)
and 1.33 (CI: 1.06-1.66), respectively.
In the STE-ACS populations the adjusted HRs of the
primary and secondary endpoints were 2.30 (95% CI:
1.44-3.68, p < 0.01) and 1.40 (95% CI: 1.10-1.77, p < 0.01)
in those with eGFR less than 45 compared with those
with eGFR more than 60 ml/min. Compared with those
with eGFR > 60 ml/min, the adjusted HRs of the primary
and secondary endpoints were 1.27 (95% CI: 0.74-2.19,
p = 0.393) and 0.96 (95% CI: 0.74-1.26, p = 0.784) in
those with eGFR between 45 and 60 ml/min. For the
NSTE-ACS populations the adjusted HRs of the primary
and secondary endpoints were 1.24 (95% CI: 0.62-2.47,
p = 0.549) and 1.01 (95% CI: 0.74-1.38, p = 0.933) in those
with eGFR between 45 and 60 ml/min compared with
those with eGFR more than 60 ml/min. Compared with
those with eGFR > 60 ml/min, the adjusted HRs of the
primary and secondary endpoints were 3.00 (95% CI:
1.77-5.07, p < 0.01) and 1.55 (95% CI: 1.21-1.98, p < 0.01)
in those with eGFR less than 45.
Impact of revascularization strategy and IGFR on
cardiovascular outcome
Among 2909 (94.05%) patients undergoing diagnostic
angiography, 81.53% were done within 72 hours. Fewer
IGFR patients received diagnostic angiography (90.21%
Table 1 Baseline characteristics between those with and without IGFR
Number (%)/Mean (SD) IGFR Non-IGFR All p value
(N = 1226) (N = 1867) (N = 3093)
Sex (male) 852 (69.49%) 1568 (83.99%) 2420 (78.24%) <0.01
Age (year) 70.27 ± 11.71 58.41 ± 12.50 63.11 ± 13.50 <0.01
Blood pressure (mmHg)
SBP 139.64 ± 36.36 139.08 ± 30.19 139.30 ± 32.75 0.647
DBP 78.75 ± 22.11 83.51 ± 19.84 81.63 ± 20.89 <0.01
Heart rate (beat per minute) 86.26 ± 25.82 79.66 ± 19.39 82.27 ± 22.38 <0.01
Height (cm) 162.27 ± 8.08 165.12 ± 7.54 164.00 ± 7.88 <0.01
Weight (kg) 65.56 ± 12.43 70.34 ± 12.82 68.44 ± 12.88 <0.01
Waist circumference 89.97 ± 10.01 90.64 ± 9.31 90.39 ± 9.57 0.340
Serum creatinine (mg/dL) 2.74 ± 2.59 0.94 ± 0.18 1.65 ± 1.86 <0.01
Dyslipidemia 479 (39.42%) 724 (39.14%) 1203 (39.25%) 0.873
Hypertension 936 (77.23%) 1019 (55.08%) 1955 (63.85%) <0.01
Diabetes
Treated 618 (50.78%) 491 (26.45%) 1109 (36.09%) <0.01
Diet only 44 (7.32%) 59 (12.37%) 103 (9.55%) <0.01
Smoker
Current 337 (28.13%) 948 (51.49%) 1285 (42.28%) <0.01
Former 246 (20.53%) 261 (14.18%) 507 (16.68%)
Never 615 (51.34%) 632 (34.33%) 1247 (41.03%)
Family history
Yes 134 (15.51%) 394 (26.78%) 528 (22.61%) <0.01
No 730 (84.49%) 1077 (73.22%) 1807 (77.39%)
Previous coronary artery disease 394 (32.14%) 350 (18.75%) 744 (24.05%) <0.01
Previous heart failure 118 (9.62%) 48 (2.57%) 166 (5.37%) <0.01
Previous cerebrovascular accident 169 (13.78%) 113 (6.05%) 282 (9.12%) <0.01
In-hospital cardiovascular events
Death 39 (3.18%) 11 (0.59%) 50 (1.62%) <0.01
Re-infarction 13 (1.06%) 11 (0.59%) 24 (0.78%) 0.144
Stroke 5 (0.41%) 7 (0.37%) 12 (0.39%) 0.886
Acute renal failure 54 (4.40%) 6 (0.32%) 60 (1.94%) <0.01
SBP, systolic blood pressure; DBP, diastolic blood pressure.
Figure 1 Medication use (A) during the first 24 hours, (B) at discharge between those with and without IGFR. IGFR, impaired glomerular
filtration rate; ACEI, angiotensin converting enzyme inhibitor; ARB, angiotensin receptor blocker.
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Figure 2 Kaplan-Meier survival curves of primary and secondary endpoints between those with or without IGFR among the whole
(A) and (D), STEMI (B) and (E) or NSTEMI/UA (C) and (F) populations. IGFR, impaired glomerular filtration rate; STEMI, ST-segment elevation
myocardial infarction; NSTEMI, non-ST-segment elevation myocardial infarction; UA, unstable angina; PCI, percutaneous coronary intervention;
CABG, coronary artery bypass graft.
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diagnostic angiography (51.71 ± 89.97 vs. 31.12 ± 50.04 hours,
p < 0.01) compared with non-IGFR subjects. Overall 2628
(85.31%) patients received PCI. IGFR patients had lower
percentage of received PCI compared with non-IGFR
subjects (79.97% vs. 88.52%, p < 0.01). Nevertheless, the
percentage of coronary artery bypass grafting (CABG)
in IGFR patients was higher (4.40% vs. 2.68%, p < 0.01).
Among the STE-ACS patients, 84.8% had reperfusion
therapy and 96.6% of them received primary PCI as re-
perfusion strategy. Lower percentage of IGFR patients
received reperfusion therapy compared with non-IGFR
subjects (80.29% vs. 87.05%, p < 0.01). However, the
percentages of primary PCI were similar between two
groups (97.48% vs. 97.05%, p = 0.653).
The Kaplan–Meier survival curves showed significant
interaction between revascularization strategy and IGFR
on the primary outcome. IGFR patients without invasive
strategy had the highest event rate during 1 year follow-
up in the whole, STE-ACS and NSTE-ACS populations
(all p < 0.01) (Figure 3).
In IGFR patients Cox regression analysis found invasive
strategy did not significantly reduce the primary endpoint
(adjusted HR 1.07, 95% CI: 0.57-1.98; p = 0.837) in the
STE-ACS (Figure 4A). In the NSTE-ACS population,
patients receiving either early DCA only or revascular-
ization had lower primary endpoint as compared withthose without invasive strategy (adjusted HR 0.53, 95%
CI: 0.30-0.92 and adjusted HR 0.57, 95% CI: 0.36-0.93;
p = 0.023 and 0.024, respectively) (Figure 4B and C).
Discussion and conclusion
There are three major findings in this analysis of Taiwan
ACS Full Spectrum cohort study. First, patients with
IGFR had more comorbidities but used less guideline-
recommended medicines than those without IGFR.
Second, ACS patients with IGFR were more likely to
suffer from in-hospital death and 1-year cardiovascular
events. Third, invasive strategy might be beneficial for
the IGFR subjects in the NSTE-ACS population.
Impaired eGFR and cardiovascular disease
Impaired eGFR is an important poor predictor of prog-
nosis in those with ACS [15,16]. Patients with IGFR have
more burden of coronary atherosclerosis in patients with
ACS [17]. Although there is no particular reason not to
treat IGFR patients just like patients without renal
dysfunction, physicians prescribed fewer guideline-
recommended treatments even in the absence of con-
traindications [18]. Furthermore, poor awareness of
impaired renal function and its risk in patients with
ACS is a big challenge both for the physicians and patients
[19]. As shown in our study, those with IGFR had more
comorbidities but received fewer guideline-recommended
Figure 3 Interaction between invasive strategy and IGFR on the primary outcome. (A). STEMI, (B). NSTEMI or UA and early DCAS, (C).
NSTEMI or UA and PCI. IGFR, impaired glomerular filtration rate; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; UA, unstable angina; PCI, percutaneous coronary intervention; DCAS, diagnostic coronary angiography strategy.
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prognosis in the ACS patients with IGFR. Therefore,
education and prevention strategies are very important
both for physicians and IGFR patients such as the na-
tionwide CKD Preventive Project with multidisciplinary
care program in Taiwan [4].
Reperfusion therapy of ST-elevation ACS in IGFR subjects
Underuse of reperfusion therapy is present with all levels
of renal dysfunction. Even in patients with mild impair-
ment of eGFR, reperfusion therapy is administered 30%
less frequently. The reason for underuse of reperfusion
therapy might be due to limited studies investigating the
effect of coronary reperfusion. Furthermore, the use of
fibrinolysis therapy might be ineffective and even increase
the risk of bleeding in the IGFR subjects [20,21]. There-
fore, when choosing reperfusion, primary PCI might have
greater benefit in patients with IGFR compared with fi-
brinolytic therapy [22]. As shown in our STE-ACS sub-
group, 84.8% received reperfusion therapy and only 3.4%
of them received fibrinolysis as reperfusion strategy. How-
ever, lower percentage of IGFR patients received reperfu-
sion therapy compared with non-IGFR subjects although
the percentages of primary PCI were similar between two
groups. Whether primary PCI is superior to fibrinolysis in
STE-ACS should be further investigated.
Early angiography and revascularization in
non-ST-elevation ACS
Renal dysfunction is present in one-third of patients
with NSTE-ACS [23]. Although there are limited studies
evaluating the impact of an invasive strategy on clinical
endpoints in patients with NSTE-ACS and IGFR, the
European society of cardiology guidelines suggests
CKD patients are at high risk of further ischaemic
events and therefore should be submitted to invasive
evaluation and revascularization whenever possible
[24]. PCI is also recommended in patients with CKDamenable to revascularization after careful assessment
of the risk–benefit ratio in relation to the severity of
renal dysfunction [25]. The 2011 ACCF/AHA guideline
suggests invasive strategy is reasonable in patients with
mild to moderate (stage II-III) CKD [26]. Our results
support the recommendations from current guidelines
in providing invasive management in ACS patients with
IGFR. Although IGFR patients suffering from ACS had
poorer prognosis, early diagnostic angiography with in-
tent to revascularization could improve their cardiovas-
cular outcomes in our study.
Influence of IGFR and coronary intervention on ACS subjects
Few studies investigated the influence of IGFR on car-
diovascular outcomes among ACS population receiving
coronary intervention. In patients with STE-ACS receiving
primary angioplasty, renal functional impairment based on
Cockroft-Gault creatinine clearance or serum creatinine is
associated with increased risk of mortality [27,28]. In the
New York State data, both STE-ACS and NSTE-ACS pa-
tients with IGFR and undergoing PCI have significantly
worse in-hospital outcomes [29]. In the GRACE registry
primary PCI was associated with lower in-hospital mortality
only in patients with normal renal function but no reduc-
tion in those with STE-ACS or new-onset of left bundle
branch block and renal dysfunction using the MDRD for-
mula [22]. In the SWEDEHEART study early revasculari-
zation within 14 days was associated with increased 1-year
survival in NSTE-ACS patients with mild to moderate
renal impairment, but no association was observed in those
with severe or end-stage kidney disease [9]. Hachinohe
D. et al. also found early invasive strategy is not benefi-
cial in the severe renal insufficiency population [30].
The present study found IGFR is associated with poor
cardiovascular outcome and aggressive strategy given
within 72 hours reduced the future occurrence of death,
recurrent myocardial infarction and stroke especially in
the NSTE-ACS population.
Figure 4 Effect of invasive strategy on cardiovascular events at 12 months in IGFR population. (A). STEMI, (B). NSTEMI or UA and early
DCAS, (C). NSTEMI or UA and PCI. IGFR, impaired glomerular filtration rate; STEMI, ST-segment elevation myocardial infarction; NSTEMI, non-ST-segment
elevation myocardial infarction; UA, unstable angina; PCI, percutaneous coronary intervention; DCAS, diagnostic coronary angiography strategy.
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This study has four main limitations. Firstly, it is a non-
randomized and an observational study. Nonetheless,
this study provides valuable real-world data on the current
practices across the full spectrum of ACS in a CKD en-
demic area, which could help to improve the ACS man-
agement in this population. Second, the procedural details
of revascularization strategy are not available. The le-
sion characteristics, adjunctive medication and device
use might modulate the cardiovascular outcome. Third, the
renal endpoint is not routinely collected after discharge inthis registry. Although those receiving aggressive revas-
cularization treatment had better cardiovascular outcomes,
their renal outcome is unclear. However, Inrig et al.
previously reported that ACS patients submitted to
angiography or angioplasty had no significant long-term
decrease in renal function [31]. The authors suggested
that the risk of cardiovascular death for patients with
IGFR outweighed the risk of renal function loss or de-
velopment of chronic dialysis, and angiography or PCI
should not be contraindicated in this group. Fourth,
there is no universal definition of acute renal failure in
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at the physicians’ discretion.
In conclusion in this real-word registry we found ACS
patients with IGFR received fewer evidence-based medi-
cines although having more comorbidities. Furthermore,
they were more likely to suffer from in-hospital and 1-year
cardiovascular events. Because coronary revascularization
could reduce the 1-year cardiovascular events especially in
the NSTE-ACS populations, physician should aggressively
treat IGFR population after careful assessment of the risk
and benefit.
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